Shanghai Henlius Biotech
Shanghai Henlius Biotech Inc is a Chinese biopharmaceutical company discovering, developing, and manufacturing biosimilar and novel monoclonal antibody oncology drugs. The company manufactures commercial biologics including Hanlikang (rituximab biosimilar), Hanquyou (trastuzumab biosimilar), and Serplulimab (anti-PD-1 monoclonal antibody) across commercial production facilities. Revenue is derived through commercial product sales of monoclonal antibody therapies to hospital networks alongside international licensing royalty fees from global pharma partners. Core end markets serve medical oncology clinics, hospital networks, and prescription cancer patients across China, Europe, and international export markets. Henlius Biotech holds a market-leading position in China's biopharmaceutical sector as a premier developer and producer of monoclonal antibody biosimilars. The company is headquartered in Shanghai, China, operating under Fosun Pharma, with shares traded on the Stock Exchange of Hong Kong.
3 of the funds FundTelligence covers report a position in Shanghai Henlius Biotech.
- Legal name
- Shanghai Henlius Biotech Inc
- Sector
- Health Care
- Country
- China
- Funds holding it
- 3
Funds holding Shanghai Henlius Biotech
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.09 % (full portfolio disclosed, October 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)